Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.95 |
| ▸ | LMNA | P02545 | 1/20 | 0.95 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Orotic Acid SCHEMBL29394966 | 0.98 | ALDH1A1 (1.00) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL431534 | 0.98 | ALDH1A1 (1.00) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL20865 | 0.98 | ALDH1A1 (1.00) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL366203 | 0.95 | ALDH1A1 (0.95) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL16916880 | 0.95 | ALDH1A1 (0.95) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL23859825 | 0.95 | ALDH1A1 (0.95) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL11903511 | 0.95 | ALDH1A1 (0.95) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL9726379 | 0.95 | ALDH1A1 (0.95) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL1852415 | 0.95 | ALDH1A1 (0.95) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL16194627 | 0.95 | ALDH1A1 (0.95) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 678 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122031707-A | Composite targeting medicine for targeted alleviation of Alzheimer disease | 陈小军 | 2026-05-15 | — | — | CN | claimed |
| EP-4735120-A2 | CHEMICALLY INDUCED REPROGRAMMING TO REVERSE AGING | President and Fellows of Harvard College (US) | 2026-05-06 | — | — | EP | claimed |
| US-20260071247-A1 | PRODUCTS FOR REGULATION OF EUKARYOTIC AND MICROBIAL CELLS GROWTH | TETS VICTOR (US) | 2026-03-12 | — | — | US | claimed |
| US-20260071249-A1 | PRODUCTS FOR REGULATION OF EUKARYOTIC AND MICROBIAL CELLS GROWTH | TETS VICTOR (US) | 2026-03-12 | — | — | US | claimed |
| EP-4659754-A1 | USE OF LITHIUM-CONTAINING COMPOUNDS IN TREATMENT OF TUMORS | Institute of Basic Medical Sciences Chinese Academy of Medical Sciences (CN) | 2025-12-10 | — | — | EP | claimed |
| US-20250345362-A1 | MULTI-IONIC COMPLEX FOR THE PREVENTION OR TREATMENT OF INFLAMMATION | YNIOS PHARMA (BE) | 2025-11-13 | — | — | US | claimed |
| US-20250276008-A1 | USE OF LITHIUM-CONTAINING COMPOUNDS IN TREATMENT OF TUMORS | INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2025-09-04 | — | — | US | claimed |
| US-20250228889-A1 | METHODS AND COMPOSITIONS FOR TREATING HEART CONDITIONS | LUENINGHOENER CATHERINE (US) | 2025-07-17 | — | — | US | claimed |
| WO-2025064524-A1 | CONTAMINANT PRECIPITATION COMPOSITIONS AND METHODS OF USE | LOCUS SOLUTIONS IPCO, LLC (US) | 2025-03-27 | — | — | WO | claimed |
| EP-4525889-A1 | MULTI-IONIC COMPLEX FOR THE PREVENTION OR TREATMENT OF INFLAMMATION | YNIOS Pharma (BE) | 2025-03-26 | — | — | EP | claimed |
| US-5223271-A | Topical; combatting molluscum contagiosum; skin lesions | EFAMOL HOLDINGS PLC (GB) | 1993-06-29 | — | — | US | claimed |
| EP-0484112-A2 | Use of lithium in the treatment or prophylaxis of Molluscum contagiosum | SCOTIA HOLDINGS PLC (GB) | 1992-05-06 | — | — | EP | claimed |
| US-5080909-A | Lithium Salt, Vidarabine, Synergistic | EFAMOL LIMITED (GB) | 1992-01-14 | — | — | US | claimed |
| EP-0432700-A2 | Use of lithium compounds for the treatment of combination skin | EFAMOL HOLDINGS PLC (GB) | 1991-06-19 | — | — | EP | claimed |
| EP-0132126-B1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF THE SKIN | SCOTIA PHARMACEUTICALS LIMITED (GB) | 1991-04-10 | — | — | EP | claimed |
| EP-0135312-B1 | ANTI-VIRAL COMPOSITIONS | SCOTIA PHARMACEUTICALS LIMITED (GB) | 1989-12-27 | — | — | EP | claimed |
| US-4886670-A | LITHIUM SALT AND ACYLCLOVIR; TOPICAL; HERPES | EFAMOL LIMITED (GB) | 1989-12-12 | — | — | US | claimed |
| EP-0305097-A2 | Nutritional supplement | SCOTIA HOLDINGS PLC (GB) | 1989-03-01 | — | — | EP | claimed |
| EP-0135312-A2 | Anti-viral compositions | SCOTIA PHARMACEUTICALS LIMITED (GB) | 1985-03-27 | — | — | EP | claimed |
| EP-0132126-A1 | Methods and compositions for the treatment of the skin | SCOTIA PHARMACEUTICALS LIMITED (GB) | 1985-01-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260071249-A1 | PRODUCTS FOR REGULATION OF EUKARYOTIC AND MICROBIAL CELLS GROWTH | EIF2A, EIF6, TUFM | ALDH1A1 4636/4885LMNA 2991/4885CYP2C19 4413/4885 |
| US-20260071247-A1 | PRODUCTS FOR REGULATION OF EUKARYOTIC AND MICROBIAL CELLS GROWTH | AMPD1, TUFM, AMPD3 | ALDH1A1 4680/4885LMNA 2516/4885CYP2C19 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.